.jpg)
SPINE
Annual infusion of zoledronic acid reduces days of back pain, disability, and bed rest
This report has been verified
by one or more authors of the
original publication.
J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292
In a secondary prespecified analysis, 7736 postmenopausal women with osteoporosis were examined to evaluate the effect of once-yearly zoledronic acid on improving back pain and disability. Patients received either a single 15 minute intravenous fusion of zoledronic acid (5 mg) or placebo at baseline, 12 months, and 24 months. The assessment at 36 months indicated that zoledronic acid significantly reduced the number of days with back pain when compared to placebo. Additionally, zoledronic acid reduced the number of days of limited activity due to back pain and limited activity and bed rest after a fracture.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
